Claims for Patent: 7,432,294

Summary for Patent: 7,432,294

Title:	Pharmaceutical formulations
Abstract:	Improved pharmaceutical compositions are provided comprising one or more solubilized HIV protease inhibiting compounds having improved solubility properties in a medium and/or long chain fatty acid, or mixtures thereof, a pharmaceutically acceptable alcohol, and water.
Inventor(s):	Alani; Laman (Morris Plains, NJ), Ghosh; Soumojeet (Lansdale, PA)
Assignee:	Abbott Laboratories (Abbott Park, IL)
Application Number:	11/546,673
Patent Claims:	1. A pharmaceutical composition comprising a solution which comprises: (a) (2S,3S,5S)-5-(N-(N-((N-methyl-N-((2-isopropyl-4-thiazolyl)-methyl)ami- no)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxy-carbonyl)-amino-1- ,6-diphenyl-3-hydroxyhexane (ritonavir), or a combination of ritonavir and another HIV protease inhibiting compound; (b) a pharmaceutically acceptable medium and/or long chain fatty acid in an amount of from 30% to 75% by weight of said solution; (c) water in an amount of from 0.4% to 3.5% by weight of said solution; and, optionally, (d) a pharmaceutically acceptable surfactant. 2. The composition according to claim 1, wherein said solution comprises ritonavir and said another HIV protease inhibiting compound. 3. The composition according to claim 2, wherein said another HIV protease inhibiting compound is (2S,3S ,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyr- imid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane (ABT-378). 4. The composition according to claim 2, wherein said another HIV protease inhibiting compound is a compound selected from the group consisting of: (1) (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahy- dropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane, (2) N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-( 1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentane- amide (indinavir), (3) N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3 (S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS ,8aS)-isoquinoline-3 (S)-carboxamide (saquinavir), (4) 5(S)-Boc-amino-4(S)-hydroxy-6-phenyl-2(R)-phenylmethylhexanoyl-(L)-Val-(L- )-Phe- morpholin-4-ylamide, (5) 1-Naphthoxyacetyl-beta-methylthio-Ala-(2S,3 S)-3-amino-2-hydroxy-4-butanoyl 1,3-thiazolidine-4-t-butylamide, (6) 5-isoquinolinoxyacetyl-beta-methylthio-Ala-(2S ,3S)-3-amino-2-hydroxy-4-butanoyl-1,3- thiazolidine-4-t-butylamide, (7) [1S-[1R-(R-),2S *])-N.sup.1[3-[[[(1,1-dimethylethyl)amino]carbonyl](2-methylpropyl)amino]- -2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butaned- iamide, ##STR00011## ##STR00012## or a pharmaceutically acceptable salt thereof. 5. The composition according to claim 1, wherein said pharmaceutically acceptable surfactant which is in an amount of from 2% to 20% by weight of said solution. 6. The composition according to claim 1, wherein said solution comprises ritonavir, or a combination of ritonavir and said another HIV protease inhibiting compound, in an amount of from 10 to 40% by weight of said solution. 7. The composition of claim 1, wherein said solution comprises water in an amount of from 0.4% to 1.5% by weight of said solution. 8. The composition according to claim 1, wherein said pharmaceutically acceptable medium and/or long chain fatty acid is a mono-unsaturated C.sub.16-C.sub.20 fatty acid which is liquid at room temperature. 9. The composition according to claim 1, wherein said pharmaceutically acceptable medium and/or long chain fatty acid is oleic acid. 10. The composition according to claim 1, wherein comprises oleic acid in an amount of from 30% to 75% by weight of said solution. 11. The composition according to claim 1, wherein said solution comprises polyoxyl 35 castor oil. 12. The composition according to claim 1, wherein said solution comprises: (a) ritonavir in an amount from 1% to 30% by weight of said solution; (b) a pharmaceutically acceptable medium and/or long chain fatty acid in an amount of from 30% to 75% by weight of said solution; (c) water in an amount of from 0.4% to 3.5% by weight of said solution; and (d) a pharmaceutically acceptable surfactant in an amount of from 0% to 20% by weight of said solution. 13. The composition of claim 1, wherein said solution comprises: (a) a combination of ritonavir and (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahyd- ropyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of from 1% to 45% by weight of said solution; (b) a pharmaceutically acceptable medium and/or long chain fatty acid in an amount of from 30% to 75% by weight of said solution; (d) water in an amount of from 0.4% to 3.5% by weight of said solution; and (e) a pharmaceutically acceptable surfactant in an amount of from 0% to 20% by weight of said solution. 14. The composition according to claim 1, wherein said solution comprises: (a) ritonavir in an amount from 1% to 30% by weight of said solution; (b) oleic acid in an amount of from 30% to 75% by weight of said solution; (c) water in an amount of from 0.4% to 3.5% by weight of said solution; and (d) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution. 15. The composition of claim 14, wherein said solution comprises polyoxyl 35 castor oil in an amount of from 2.5% to 10% by weight of said solution. 16. The composition of claim 1, wherein said solution comprises: (a) a combination of ritonavir and (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahyd- ropyrimid-2-onyl)-3-methylbutanoyl]-amino-1,6-diphenylhexane, in an amount of from 1% to 45% by weight of said solution; (b) oleic acid in an amount of from 30% to 75% by weight of said solution; (c) water in an amount of from 0.4% to 3.5% by weight of said solution; and (d) polyoxyl 35 castor oil in an amount of from 0% to 20% by weight of said solution. 17. The composition of claim 16, wherein said solution comprises polyoxyl 35 castor oil in an amount of from 2.5% to 10% by weight of said solution. 18. The composition according to claim 1, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution. 19. The composition according to claim 2, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution. 20. The composition according to claim 3, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution. 21. The composition according to claim 10, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution. 22. The composition according to claim 12, further comprising a hard or soft elastic gelatin capsule which encapsulates said solution. 23. A pharmaceutical composition comprising a solution which comprises: (a) ritonavir, or a combination of ritonavir and another HIV protease inhibiting compound; (b) a mixture of pharmaceutically acceptable medium and/or long chain fatty acids in an amount of from 30% to 75% by weight of said solution; (c) water in an amount of from 0.4% to 3.5% by weight of said solution; and, optionally, (d) a pharmaceutically acceptable surfactant. 24. The composition according to claim 23, wherein said mixture of pharmaceutically acceptable medium and/or long chain fatty acids is a mixture of mono-unsaturated C.sub.16-C.sub.20 fatty acids which are liquids at room temperature. 25. The composition according to claim 23, wherein said mixture of pharmaceutically acceptable medium and/or long chain fatty acids includes oleic acid.